Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix Vaccine, Administered According to a 0,6 m Schedule and a 0,1,6 m Schedule, in Healthy Children Aged Between 1-11 y at the Time of First Vaccine Dose

Trial Profile

Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix Vaccine, Administered According to a 0,6 m Schedule and a 0,1,6 m Schedule, in Healthy Children Aged Between 1-11 y at the Time of First Vaccine Dose

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Hepatitis A-hepatitis B vaccine (Primary)
  • Indications Hepatitis A; Hepatitis B
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 28 Apr 2010 Five-year follow-up results published in Vaccine.
    • 06 Nov 2008 New source identified and integrated (ClinicalTrials.gov record NCT00787449).
    • 12 Aug 2008 Actual patient number added (276) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top